ADC Therapeutics Ltd (ADCT)

Over the past six months, ADC Therapeutics SA's stock experienced several events. Strong Q4 and full year 2025 financial results led to a stock gain. An analyst reaffirmed a "Buy" rating and increased the price target. An amended HealthCare Royalty Financing Agreement was announced. Upcoming clinical catalysts, including topline results from the LOTIS-5 Phase 3 trial and complete enrollment in the LOTIS-7 trial, are anticipated. The stock has traded between $4.98 and $1.10 over the past 52 weeks, with a price of $3.74 as of April 10, 2026.

The underlying demand for ZYNLONTA in the third-line and later diffuse large B-cell lymphoma indication has remained broadly stable year-over-year. Variability in customer ordering quarter-over-quarter does not indicate a seasonal demand pattern. The nature of oncology treatments suggests that significant demand seasonality for ADC Therapeutics' products is unlikely.

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company dedicated to the discovery, development, and commercialization of highly targeted antibody-drug conjugates (ADCs) for patients with hematological malignancies and solid tumors. Their core product is ZYNLONTA (loncastuximab tesirine-lpyl), a CD19-directed ADC, which has received accelerated approval from the FDA, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for treating adult patients with relapsed or refractory large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company's pipeline includes ADC candidates like Camidanlumab tesirine (ADCT-301), ADCT-602, ADCT-601, ADCT-212, ADCT-701, ADCT-901, and pre-clinical stage ADCs targeting Claudin-6, NaPi2b, PSMA, and ASCT2.

ADC Therapeutics SA is headquartered in Lausanne, Switzerland, with additional offices in London and New York. The company's global footprint spans Europe and North America, encompassing clinical research sites and manufacturing partnerships. It generates maximum revenue from the United States, followed by Europe, the Middle East, and Africa (EMEA). The company serves customers in the United States, Switzerland, and the United Kingdom.

Specific events directly impacting ADC Therapeutics SA's brand reputation were not explicitly detailed. However, positive clinical trial updates and financial performance generally contribute to a favorable reputation. The company's focus on developing targeted therapies for cancer and its FDA-approved product, ZYNLONTA, are foundational to its scientific and commercial standing.

ADC Therapeutics SA's stock ownership includes institutional, insider, and retail investors. Approximately 65.23% of the company's stock is owned by institutional shareholders, insiders own about 39.49%, and retail investors hold approximately 14.29%. Major institutional owners include Redmile Group, LLC, Prosight Management, LP, and Orbimed Advisors Llc. Redmile Group LLC is the largest individual shareholder, owning 38.60 million shares, representing 30.38% of the company. Hans Peter Wild is another significant individual owner.